<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25850884</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1473-5741</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anti-cancer drugs</Title>
                <ISOAbbreviation>Anticancer Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.</ArticleTitle>
            <Pagination>
                <MedlinePgn>716-27</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/CAD.0000000000000237</ELocationID>
            <Abstract>
                <AbstractText>Glioblastoma is a disease characterized by rapid invasive tumour growth. Studies on the proapoptotic CD95/CD95L signalling pathway recently suggested a significant contribution of CD95 signalling towards the high degree of motility in glioma cells. Apogenix has developed APG101, a clinical phase II compound designed to bind and neutralize CD95L, and thus to interfere with CD95/CD95L-based signalling. APG101 has shown clinical efficacy in a controlled randomized phase II trial in patients with recurrent glioma. Because APG101 is not cytotoxic to tumour cells in vitro, we postulated that the anti-invasive function of APG101 is the main mechanism of action for this compound. Using three-dimensional spheroid invasion assays in vitro and in murine brain tissue cultures, we found that knockdown of endogenous CD95L reduced the invasive phenotype in our two glioblastoma model cell lines U87-MG and U251-MG. Invasion was restored in CD95L knockdown cells upon the addition of soluble recombinant CD95L and this effect was inhibited by APG101. We conclude that CD95L from autocrine and paracrine sources contributes towards the invasive phenotype of glioblastoma cells and that APG101 acts as a suppressor of proinvasive signalling by the CD95/CD95L pathway in glioblastoma. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Merz</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>aApogenix GmbH bDivision of Signal Transduction and Growth Control DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strecker</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sykora</LastName>
                    <ForeName>Jaromir</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hill</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fricke</LastName>
                    <ForeName>Harald</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Angel</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gieffers</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peterziel</LastName>
                    <ForeName>Heike</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Anticancer Drugs</MedlineTA>
            <NlmUniqueID>9100823</NlmUniqueID>
            <ISSNLinking>0959-4973</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019014">fas Receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>F333OQQ9UV</RegistryNumber>
                <NameOfSubstance UI="C574675">APG101</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019014" MajorTopicYN="N">fas Receptor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25850884</ArticleId>
            <ArticleId IdType="doi">10.1097/CAD.0000000000000237</ArticleId>
            <ArticleId IdType="pmc">PMC4484665</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>EMBO J. 2004 Aug 4;23(15):3175-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15272306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 1997 Apr 21;185(8):1487-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9126929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FASEB J. 2005 Apr;19(6):620-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15670977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neuropathol Exp Neurol. 2005 Sep;64(9):754-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16141784</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Differ. 2006 Jul;13(7):1156-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16254573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2007 May 4;129(3):447-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17482535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2008 Mar;13(3):235-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18328427</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 May 27;465(7297):492-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20505730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2010;9:161</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20573240</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2011 Mar 4;144(5):646-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21376230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Biol. 2011 Jun;9(6):e1001090</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21713032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2011 Nov 15;10(22):3857-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22064519</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Neurosci. 2013 Aug;16(8):1154-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23792946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Nov 15;73(22):6711-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24072745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2014 Jun;20(6):607-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24793239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2014 Dec 15;20(24):6304-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25338498</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2015 Jan 29;34(5):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24488013</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Oct 12;407(6805):789-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11048730</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>